Deep Cure
DeepCure is an AI-driven therapeutics company focused on developing novel small molecule drugs for immune and inflammatory diseases. Their proprietary Inspired Chemistry™ platform automates chemical synthesis, enabling rapid design and testing of diverse compounds for challenging targets. The company has advanced two development candidates: DC-15442, an oral STAT6 inhibitor, and DC-9476, a selective BRD4 (BD2) inhibitor. These candidates show promising efficacy in preclinical models for conditions like rheumatoid arthritis and type 2 inflammation, aiming to provide oral alternatives to injectable biologics. DeepCure collaborates with leading research institutions and leverages AI and machine learning to tackle historically undruggable targets, focusing on achieving true novelty in drug development.
Deep Cure
DeepCure is an AI-driven therapeutics company focused on developing novel small molecule drugs for immune and inflammatory diseases. Their proprietary Inspired Chemistry™ platform automates chemical synthesis, enabling rapid design and testing of diverse compounds for challenging targets. The company has advanced two development candidates: DC-15442, an oral STAT6 inhibitor, and DC-9476, a selective BRD4 (BD2) inhibitor. These candidates show promising efficacy in preclinical models for conditions like rheumatoid arthritis and type 2 inflammation, aiming to provide oral alternatives to injectable biologics. DeepCure collaborates with leading research institutions and leverages AI and machine learning to tackle historically undruggable targets, focusing on achieving true novelty in drug development.